Discovery and Characterization of Dbf4b: A Promising RNA Molecule as A Drug Target Or Biomarker

Target Name: DBF4B

NCBI ID: G80174

DBF4B

Discovery and Characterization of Dbf4b: A Promising RNA Molecule as A Drug Target Or Biomarker

Dbf4b (DICER-like 4B) is a non-coding RNA molecule that has been found to be highly expressed in various tissues and cell types, including the brain, heart, and pancreas. Its function and significance as a drug target or biomarker remains poorly understood, but research has shown that it plays a critical role in several cellular processes, including cell adhesion, migration, and transcriptional regulation.

The discovery and characterization of Dbf4b

Dbf4b was first identified as a novel non-coding RNA molecule using RNA sequencing (RNA-seq) data from the brain and other tissues. Since its discovery, several studies have further characterized its expression and function in various cellular contexts.

One of the most significant findings of these studies is that Dbf4b is highly expressed in the brain, where it is expressed at levels of up to 10% of the total RNA in the brain. This finding suggests that Dbf4b may play a critical role in the development and maintenance of brain function, and that it may be a promising drug target or biomarker for the treatment of neurological disorders.

Other functions and roles of Dbf4b

In addition to its role in cell adhesion and migration, Dbf4b has also been shown to play a critical role in transcriptional regulation. Studies have shown that Dbf4b can interact with the protein silencing factor RNA-binding protein (RBP) and the RNA-binding DNA Binding protein RNA-binding DNA binding protein (RBDF2) to regulate gene expression.

Moreover, Dbf4b has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. For instance, studies have shown that Dbf4b can inhibit the activity of the protein kinase PDK4, which is involved in cell growth and angiogenesis.

The potential implications of Dbf4b as a drug target or biomarker

The findings of studies that have characterized Dbf4b's functions in cell adhesion, migration, and transcriptional regulation suggest that it may be a promising drug target or biomarker for the treatment of a variety of disorders. For instance, Dbf4b's role in cell migration and adhesion may make it a potential target for therapies that aim to improve tissue repair and regeneration following injury or disease.

In addition, Dbf4b's role in transcriptional regulation suggests that it may be a potential target for drugs that aim to improve gene expression and cell function in a variety of diseases. For instance, the regulation of gene expression by Dbf4b may be involved in the development of neurodegenerative diseases, and therefore, targeting Dbf4b may be a promising approach to the development of new treatments for these disorders.

Conclusion

Dbf4b is a non-coding RNA molecule that has been found to be highly expressed in various tissues and cell types, including the brain. Its function and significance as a drug target or biomarker remains poorly understood, but research has shown that it plays a critical role in several cellular processes, including cell adhesion, migration, and transcriptional regulation. Further studies are needed to fully understand the potential implications of Dbf4b as a drug target or biomarker, and to develop new treatments based on its unique properties.

Protein Name: DBF4 Zinc Finger B

Functions: Regulatory subunit for CDC7 which activates its kinase activity thereby playing a central role in DNA replication and cell proliferation. Required for progression of S and M phases. The complex CDC7-DBF4B selectively phosphorylates MCM2 subunit at 'Ser-40' and then is involved in regulating the initiation of DNA replication during cell cycle

The "DBF4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBF4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets